BioDrive, Inc. – FDA Warning Letter, Aug 3, 2026

BioDrive, Inc. received a formal Warning Letter from the FDA on August 24, 2026, regarding its dietary supplement, Evolv GLP-1 Biomimetic. The central issue is the inclusion of a component known as "EV1-Peptide." Under the regulatory framework of the Federal Food, Drug, and Cosmetic Act, this substance is classified as a new dietary ingredient because there is no record of it being marketed in the United States prior to October 1994. Consequently, the company was required to demonstrate that the ingredient is safe for public consumption. The FDA determined that BioDrive failed to provide sufficient safety data. Despite the company filing two separate safety notifications, the FDA issued objections citing concerns over potential toxicity and risks of adverse clinical effects. By ignoring these warnings and continuing to market the product, BioDrive is in violation of federal law, as the supplement is legally considered unsafe or "adulterated." To resolve this matter, the FDA requires BioDrive to submit a written response within 15 working days. This response must detail the specific actions taken to address the violations and include documentation of steps taken to prevent their recurrence. The agency warned that failure to comply could result in legal action, including product seizures or court-ordered injunctions.